

Press release 2016-02-19

## **WntResearch recruits new CFO**

**WntResearch today announce that Per-Ola Forsberg has been appointed new Chief Financial Officer (CFO).**

Per-Ola Forsberg will from March 1<sup>st</sup> 2016 take over as CFO of WntResearch. His most recent assignment was as CFO at Idogen AB. Per-Ola Forsberg has extensive experience as CFO of several life science and research companies and was also involved in the introduction of Probi and LIDDS on the Nasdaq Stock Exchange.

*"I welcome Per-Ola to the company. With his broad expertise, he will for sure contribute in our intensive efforts to further develop WntResearch. He has valuable knowledge from positions as CFO in other listed companies and long experience from the pharmaceutical and biotechnology industry,"* says Henrik Lawaetz, CEO of WntResearch.

*"WntResearch is a very exciting company and I am happy to be involved in the future development of the company,"* says Per-Ola Forsberg.

### **For additional information please contact:**

Henrik Lawaetz, CEO WntResearch,  
Phone: +46 (0) 72 702 4694  
E-mail: [hl@wntresearch.com](mailto:hl@wntresearch.com)

### **About WntResearch**

*WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. WntResearch AB is a public company listed on AktieTorget.*

*For more information see <http://www.wntresearch.com>*